TF

Theodore Friedmann

University of California: 12 patents #451 of 18,278Top 3%
CH City Of Hope: 3 patents #134 of 524Top 30%
CV Chiron Viagene: 1 patents #7 of 18Top 40%
📍 Village of La Jolla, CA: #308 of 2,316 inventorsTop 15%
🗺 California: #46,935 of 386,348 inventorsTop 15%
Overall (All Time): #388,394 of 4,157,543Top 10%
13
Patents All Time

Issued Patents All Time

Showing 1–13 of 13 patents

Patent #TitleCo-InventorsDate
7060688 Products and methods for controlling the suppression of the neoplastic phenotype Wen-Hwa Lee, Huei-Jen Su Huang, Eva Lee, Jiing-Kuan Yee 2006-06-13
6451304 Method for retrovirus vector production by separated gag and pol expression Atsushi Miyanohara 2002-09-17
6432705 Inducible expression system Jiing-Kuan Yee, Shin-Tai Chen 2002-08-13
6171862 Transfection in serum-containing media Akihiro Abe, Atsushi Miyanohara 2001-01-09
6133027 Inducible expression system Jiing-Kuan Yee, Shin-Tai Chen 2000-10-17
5817491 VSV G pseusdotyped retroviral vectors Jiing-Kuan Yee, Nobuhiko Emi, Douglas J. Jolly, Jack R. Barber 1998-10-06
5762926 Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system Fred H. Gage, Malcolm Schinstine, Jasodhara Ray, Michael D. Kawaja, Michael Rosenberg +1 more 1998-06-09
5739018 Packaging cell lines for pseudotyped retroviral vectors Atsushi Miyanohara, Jiing-Kuan Yee, Shin-Tai Chen, Charles E. Prussak 1998-04-14
5674486 Cancer immunotherapy with carrier cells Robert Sobol, Fred H. Gage, Ivor Royston 1997-10-07
5670354 Use of VSV-G pseudotyped vectors for transfer of genes into embryos Jane C. Burns, Jiing-Kuan Yee 1997-09-23
5650148 Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system Fred H. Gage, Michael Rosenberg, Jon Wolff, Malcolm Schinstine, Michael D. Kawaja +1 more 1997-07-22
5512421 Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors Jane C. Burns, Jiing-Kuan Yee 1996-04-30
5082670 Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system Fred H. Gage, Michael Rosenberg 1992-01-21